LNTH vs. NEOG, QDEL, RIOT, NTLA, CLDX, MYGN, ACHV, TKNO, VNRX, and ABIO
Should you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include Neogen (NEOG), QuidelOrtho (QDEL), Riot Platforms (RIOT), Intellia Therapeutics (NTLA), Celldex Therapeutics (CLDX), Myriad Genetics (MYGN), Achieve Life Sciences (ACHV), Alpha Teknova (TKNO), VolitionRx (VNRX), and ARCA biopharma (ABIO).
Neogen (NASDAQ:NEOG) and Lantheus (NASDAQ:LNTH) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.
96.7% of Neogen shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 0.7% of Neogen shares are held by insiders. Comparatively, 1.5% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Lantheus had 3 more articles in the media than Neogen. MarketBeat recorded 10 mentions for Lantheus and 7 mentions for Neogen. Neogen's average media sentiment score of 0.94 beat Lantheus' score of 0.77 indicating that Lantheus is being referred to more favorably in the news media.
Neogen has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.
Neogen currently has a consensus target price of $22.50, suggesting a potential upside of 38.55%. Lantheus has a consensus target price of $99.17, suggesting a potential upside of 21.62%. Given Lantheus' higher possible upside, equities analysts plainly believe Neogen is more favorable than Lantheus.
Neogen received 2 more outperform votes than Lantheus when rated by MarketBeat users. However, 65.21% of users gave Lantheus an outperform vote while only 57.19% of users gave Neogen an outperform vote.
Lantheus has a net margin of 33.72% compared to Lantheus' net margin of 0.17%. Neogen's return on equity of 54.10% beat Lantheus' return on equity.
Lantheus has higher revenue and earnings than Neogen. Lantheus is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.
Summary
Lantheus beats Neogen on 13 of the 18 factors compared between the two stocks.
Get Lantheus News Delivered to You Automatically
Sign up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lantheus Competitors List
Related Companies and Tools
